Best Infectious Diseases Companies in Sweden
The 56 best Infectious Diseases companies in Sweden in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Scandinavian Biopharma.
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Infectious Diseases companies in Sweden
| # | Company | Last round | Disclosed funding | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | AB bioMérieux Producer of diagnostics products. The company's product line, Etest®, is used to determine the exact Minimum… | — | — | 23 | — | — | — | — |
| 2 | AegirBio AegirBio AB is a Swedish diagnostic company that offers tests to monitor and optimize the dosage of… | — | — | 15 | — | — | 20 patents Point‑of‑care biosensor and lateral‑flow immunoassay platforms for thyroid and infectious disease diagnostics | — |
| 3 | alteco medical Alteco Medical has developed a new method for treating sepsis. (Blood poisoning). | — | — | 5 | — | — | 39 patents Selective binding matrices and devices for separating biomarkers from body fluids | — |
| 4 | Apodemus Developing antiviral treatments and diagnostic tools for viral infections. | — | — | — | Johan Claesson Founder | — | 27 patents Design and synthesis of pyrazolo[1,5-a]pyrimidine/ triazine small‑molecule therapeutics and antivirals | — |
| 5 | Bioimics Antibiotics targeting multi-drug-resistant bacteria. | — | — | 4 | — | — | 27 patents Novel heterocyclic antimicrobial agents for treating bacterial and fungal infections | — |
| 6 | Biomedrex Developer of drugs for viral diseases | — | — | 8 | Theodor Pramer CEO | — | 4 patents Manufacturing viral gene‑therapy vectors and CRISPR‑based biopharmaceuticals. | — |
| 7 | Biosergen Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical… | — | — | 4 | — | — | — | — |
| 8 | Crucell Sweden Developer, manufacturer, marketer and distributor of vaccines. | — | — | 115 | — | — | — | — |
Top 12 Infectious Diseases companies in Sweden
#1
Series B · Gothenburg, Vastra Gotaland County · founded 2018 · 7 employees$3.5Mraised▾
Amferia is developing an anti-infective technology. The company has developed its proprietary patented technology which consists of anti-bacterial polymers that can kill bacteria including antibiotic-resistant bacteria. The material is selective and targets only bacteria and is non-toxic to human cells.
- Dec 2025Series B$4.1M
- Sep 2024Series A$1.3M
- Jan 2023Series A$1.5M
- Feb 2020Grant (prize money)$55K
#2
Seed · Lund, Skane County · founded 2014 · 20 employees$7.1Mraised▾
Developer of nanofiber-based cell culture products for upstream bioprocessing. The company's technology is scalable and customizable for research and development. It enables the development of improved cell culture products. The products are for cell and gene therapy and novel vaccines production. The company has implemented good manufacturing practice processes for production. It collaborates with contract development and manufacturing organizations and biopharmaceutical companies.
- Sep 2024Seed$3.5M
- Oct 2023Seed$3.5M
- Jul 2023Seed—
#3
Seed · Gothenburg, Vastra Gotaland · founded 2023$541.3Kraised▾
Developer of biosensing technology for rapid bacteria, virus, fungi, detection. The technology offers portable bacteria detection and quantification. The company's method can detect any bacteria, virus, fungi, or molecule.
- 2025Seed$541.3K
#4
Early Stage · Solna, Stockholm County · founded 1994 · 5 employees$2.4Mraised▾
Developer of antibiotics against pathogenic bacteria. The company is developing "EbsArgent" which combines ebselen and silver a synthetic organoselenium drug molecule with antimicrobial activity silver is commonly used as an antibiotic coating on medical devices and wound dressings against pathogenic bacteria.
#5
Series A · Lund, Skane County · founded 2015 · 3 employees$1.6Mraised▾
Provider of therapeutics for treating vaginal microbial infections. It offers non-antibiotic based small molecule drug pHyph which is under clinical study 2, it has the ability to lower the pH and is effective against both bacterial and fungal infection.
- Feb 2024Grant (prize money)$2.7M
- Jun 2023Series A$1.4M
- Jan 2020Grant (prize money)$2.2M
- May 2019Grant (prize money)$55.7K
#6
Funding Raised · Solna, Stockholm County · founded 2013 · 27 employees$29.7Mraised▾
Scandinavian develops vaccines for treating diarrhea. It also provides BCG Vaccine AJVaccines contains bacteria of the type Mycobacterium Bovis BCG and is used for protection against tuberculosis.
- Feb 2020Grant (prize money)$11.4M
- Nov 2019Grant (prize money)$3.3M
- Jan 2019Grant (prize money)$8.4M
- Jun 2017Grant (prize money)$3.4M
#7
Public · Uppsala, Uppsala County · founded 2008 · 149 employees$18.3Mraised▾
Q-linea develops fully automated platforms for pathogen detection. It uses a combination of circle-to-circle DNA amplification and proprietary 'padlock' probes for sensitive detection of bacteria and probes. The company claims that its technology can be heavily multiplexed, and allows up to 20000-plex measurements. Its flagship product ASTrID can use whole blood samples to perform both molecular pathogen detection and phenotypic antibiotic susceptibility in four and six hours respectively. First application is diagnosis of sepsis. In addition, Q-linea also has the AQUILA line of analyzers for the detection of biological warfare agents like anthrax.
- Mar 2018Series B$18.3M
#8
Series A · Solna, Stockholm County · founded 2015 · 32 employees$1.2Mraised▾
EMPE Diagnostics is developing diagnostic solutions for early-stage, point-of-care confirmatory diagnostics for infectious diseases with a special focus on antimicrobial resistance. Its flagship products "miniMDR-TB" allows differentiating single-nucleotide variants of the most common mutations [rpoB 531 (TCG/TTG) and katG 315 (AGC/ACC)] causing MDR-TB. This molecular diagnostic test produces visual signals on lateral flow cassettes corresponding to the respective genotype-tags on lateral flow strips, in less than 60 min. Another product "miniXDR-TB test" allows detection directly either on microscopy positive samples or after considering results from the miniMDR-TB test. It can detect the presence of MTC, katG 315 wt, katG 315 ACC, inhA -15 wt, inhA -15T, rpoB 531 wt, rpoB 531 TTG, rpoB 526 wt, rpoB 526 TAC, gyrA 90 wt, gyrA 90 GTG, gyrA 94 wt, gyrA 94 GGC, rrs 1401 wt,and rrs 1401 G in less than 60 minutes.
- Feb 2023Grant (prize money)$52.9K
- Mar 2021Grant (prize money)$3M
- Mar 2020Grant (prize money)$55.1K
- Dec 2019Grant (prize money)$55.1K
#9
Series B · Uppsala, Uppsala County · founded 1984 · 45 employees$11.5Mraised▾
Provider of molecular diagnostic kits for diagnosis and monitoring of viral infections. Specifically, the company's area of expertise is in assays that measure reverse transcriptase activity. Its flagship product ExaVir Load is an RT-PCR assay for monitoring viral load in HIV+ patients. Cavidi is also developing a solution for monitoring viral resistance to HIV drugs. Other products in the company's portfolio include diagnostic kits for the detection of lentiviruses, C-type retroviruses, Mn and/or Mg dependent retroviruses, and xenotropic murine leukemia virus-related virus.
#10
Funding Raised · Lund, Skane County · founded 2015$2.5Mraised▾
Developer of drugs for the treatment of cancer and infections. The company's drug development pipeline includes Alpha1H for brain tumors and Bovine HAMLET, BAMLET, for colon cancer and oral cancer. Also, it develops drugs for antibiotic drug-resistant bacteria.
- May 2022Grant (prize money)$53.8K
- Jun 2020Grant (prize money)$2.4M
#11
Funding Raised · Stockholm, Stockholm County · founded 2012 · 6 employees$2.5Mraised▾
Abera is a Swedish, early stage vaccine development company using a platform based on Gram-negative bacteria and derived Outer Membrane Vesicle (OMV) technology. These Outer Membrane Vesicles (OMVs) that can be decorated on the surface with multiple antigens of choice at a high density. These vaccines are being developed for oral and nasal administration Current product pipeline includes preclinical prophylactic candidates for Pneumococcal disease, Tuberculosis, Chlamydia and therapeutic vaccines for cancer.
- Nov 2021Grant (prize money)$2.2M
- Jan 2019Grant (prize money)$323.2K
- Grant (prize money)—
#12
Seed · Malmo, Skane County · founded 2016 · 10 employees$5.2Mraised▾
2A Pharma is developing novel vaccines using adeno-associated virus-like particle (AAVLP) technology for the treatment of cancer and infectious diseases (viral). The company has licensed the AAVLP technology from Medigene AG. As of Jan 2017, the company has not disclosed its drug programs.
- Jun 2018Seed$2.2M
- Dec 2016Seed$3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Diagnostics is moving in Sweden
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 383 Sweden-affiliated papers.
- Karolinska Institutet151
- Karolinska University Hospital66
- Uppsala University52
- Lund University42
- University of Gothenburg33
- Liquid biopsy3→15
- Point-of-care testing2→9
- Computational biology1→5
- Circulating tumor cell1→5
- Biomarker2→4
- Liquid biopsy3→35
- Biomarker1→19
- Internal medicine2→14
- Cancer3→13
- Point-of-care testing15→20
- Liquid biopsy3→7
- Precision medicine1→4
- Computational biology3→5
- Internal medicine3→5
- Population3→4
Where diagnostics is researched across Sweden
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.